National Research (NASDAQ:NRC) Earns Mkt Outperform Rating from Analysts at Citizens Jmp
Citizens JMP initiated coverage of National Research (NASDAQ:NRC) with a “mkt outperform” rating and a $23.00 price target, implying 22.1% upside from $18.84. Separately, Weiss Ratings upgraded NRC to “hold (c-)” from “sell (d+)” on May 29. NRC reported Q1 EPS of $0.21 on $34.8M revenue.
How this was made
The 30-second read
Why it matters
The only new decision-relevant item is the initiation by Citizens Jmp with a stated rating and target; the rest is recap-style context (prior earnings date, general financial ratios, and 13F-style institutional stake changes).
Market read
Traders may react to the initiation/target, but there’s no new operational or regulatory catalyst in the text.
What to watch
The article also notes weak liquidity (very low volume vs average) and high leverage metrics; these can dampen follow-through from analyst headlines.
Background
The piece summarizes analyst coverage changes and includes basic trading/financial ratios plus prior-quarter earnings timing.
Ticker impact
Citizens Jmp initiated coverage on National Research with a “mkt outperform” rating and a $23 price target, implying ~22% upside from ~$18.84.
Modest positive drift possible around the initiation/target headlines; follow-through depends on subsequent analyst notes and liquidity.
The article provides a new rating/target and cites the stock’s current price, but no new company fundamentals (no earnings/guidance/contract/regulatory action).
Market effects
Limited read-across; healthcare analytics/performance-improvement names may see minor sentiment spillover from analyst coverage activity.
None indicated beyond small-cap liquidity effects.
None indicated.
Counterpoint
A single initiation with a target often has limited staying power versus catalysts like new contracts, guidance changes, or earnings surprises.
Key entities
- companyNational Research
NASDAQ-listed healthcare analytics/performance improvement firm (NRC).
